Source: Eur Respir J 2004; 23: 663-664



Rating:

Share or cite this content

Citations should be made in the following way:
Eymin B., Brambilla E.. The yin and the yang of p27Kip1 as a target for cancer therapy. Eur Respir J 2004; 23: 663-664

Member's Comments

No comment yet.

Related content which might interest you: The yin and yang of idiopathic pulmonary fibrosis Source: Eur Respir J , 49 (2) 1602316; DOI: 10.1183/13993003.02316-2016 Year: 2017 The of COPD: or balancing repair (yang) and inflammation (yin) Source: Eur Respir J 2008; 32: 1426-1427 Year: 2008 The yin and yang of immunosuppression with inhaled corticosteroids in asthma and COPD Source: Virtual Congress 2021 – Pharmacology of lung immune responses: which pathways to target! Year: 2021 Personalised pathogenetic pathways in fibrotic ILDs: the yin of pathogenetic thinking Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases Year: 2019 Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis Source: Eur Respir J 2002; 20: 703-709 Year: 2002 Bufei Yishen granules and it combined with acupoint sticking therapy suppresses inflammation in COPD rats: via JNK/p38 signaling pathway Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia Year: 2017 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs? Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Diminished expression of HOXA5 in lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003 Pathogenetic mechanisms common to disease progression in fibrotic ILDs: the yang of pathogenetic thinking Source: International Congress 2019 – Lumping and splitting of fibrotic interstitial lung diseases Year: 2019 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Late Breaking Abstract - Anaplastic Lymphoma Kinase inhibition as an effective treatment strategy against the enhanced lung carcinogenesis and cancer angiogenesis related to decreased PTPRZ1 expression Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 Monoallelic germline ATM mutation and organising pneumonia induced by radiation therapy to the breast Source: Eur Respir J 2016; 47: 997-1000 Year: 2016 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Source: Eur Respir J 2002; 19: 557-570 Year: 2002 MicroRNA-101 inhibits lung cancer growth and invasion through regulation of EZH2 Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 The role of HER-2/neu, p53, Bcl-2 and Ki-67 in patients with lung cancer Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019